1-(2,2-diphenylethyl)piperazine | 41298-46-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(2,2-diphenylethyl)piperazine
• 英文别名: 4-diphenylethylpiperazine；N-(2,2-diphenylethyl)piperazine；DPh2P；1-(2,2-diphenyl-ethyl)-piperazine
• CAS: 41298-46-8
• 化学式: C₁₈H₂₂N₂
• 分子量: 266.386
• InChiKey: OQUSCPYIGRKEOO-UHFFFAOYSA-N

物化性质

• 沸点：
  392.2±32.0 °C(Predicted)
• 密度：
  1.041±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(2,2-diphenylethyl)piperazine 生成 5-[3-(4-(2,2-diphenylethyl)piperazine-1-yl)-2-hydroxypropoxy]quinoline
  参考文献：
  名称：

  Quinoline derivatives

  摘要：

  新颖的杂环化合物，以以下通用公式表示，作为抗癌药物增效剂，对抗癌药物的纳入癌细胞具有增效作用，这些化合物通过例如将由异环化合物与环氧卤水合物反应得到的环氧化合物与胺衍生物反应合成。

  公开号：

  US05112817A1
• 作为产物：
  描述：

  2,2-diphenylethyl 4-methylbenzenesulfonate 在 氢氧化钾 作用下， 以 乙醇 、 水 为溶剂， 反应 18.0h， 生成 1-(2,2-diphenylethyl)piperazine
  参考文献：
  名称：

  New 1,3-dioxolane and 1,3-dioxane derivatives as effective modulators to overcome multidrug resistance

  摘要：

  Multidrug resistance (MDR) to antitumor agents represents a major obstacle to a successful chemotherapy of cancer. Overexpression of P-glycoprotein (p-gp) seems to be the major factor responsible for MDR. A large number of chemically unrelated compounds are known to interact with p-gp resulting in a decreasing resistance. In our efforts related to structure-activity studies of new potential MDR reversal agents we synthesized a series of compounds that differ in the aromatic core structure, the linker, and the basic moiety. For our search of new aromatic core structures we synthesized novel 2,2-diphenyl-1,3-dioxolane, 2,2- diphenyl-1,3-dioxane, and 4,5-diphenyl-1,3-dioxolane derivatives. A range of lipophilic linker structures and protonable basic moieties were synthesized and investigated to optimize the structure of the potential MDR-modulators. The compounds were tested in vitro using human Caco-2 cells. Both the cytotoxicity of the synthons and their ability to resensitize the cells were determined with a MTT assay. The results show that at low concentration various substances reverse tumor cell MDR. Some of the new structures show better effects than established modulators like trifluoperazine. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2007.01.024

文献信息

• Synthesis and Biochemical Characterization of New Phenothiazines and Related Drugs as MDR Reversal Agents
  作者：Matthias Schmidt、Marlen Teitge、Marianela E. Castillo、Tobias Brandt、Bodo Dobner、Andreas Langner

  DOI：10.1002/ardp.200800115

  日期：2008.10

  for pharmacophor structures is a promising strategy to increase the efficacy of those drugs still influencing multidrug resistance. In this study a range of phenothiazine derivatives was synthesizied with systematical variation of three molecule domains. The biochemical determination of multidrug resistance reversal activity was achieved with the crystalviolet assay on LLC‐PK1/MDR1 cells. The results

  化疗是治疗癌症最重要的方法之一。然而，化疗期间耐药性的发展是癌症患者治疗失败和生存率下降的主要原因。多药耐药 (MDR) 是 30 多年来广泛研究的耐药形式之一。ATP 结合盒蛋白家族的成员负责以 P-糖蛋白作为最具代表性的转运蛋白的多药耐药性。为了克服多药耐药性，外排泵抑制剂对转运蛋白的药理学调节似乎是首选，但临床前研究并未导致临床应用。因此，对药效基团结构进行系统研究是提高那些仍影响多药耐药性的药物疗效的有前途的策略。在这项研究中，一系列吩噻嗪衍生物合成了三个分子结构域的系统变异。多药耐药逆转活性的生化测定是通过对 LLC-PK1/MDR1 细胞的结晶紫测定实现的。将考虑文献中关于新的结构-活性关系以克服未来耐药性的假设来讨论结果。
• Substituted piperazinyl alkyl esters of
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US04603135A1

  公开（公告）日：1986-07-29

  Dihydropyridine derivatives and acid addition salts thereof which are of use as prophylactic or/and therapeutic drugs for cardiovascular diseases, said dihydropyridine derivatives having the formula ##STR1## wherein R.sup.1 is a hydrogen atom or an aryl, R.sup.2 and R.sup.3 are the same or different and each is an aryl, R.sup.4 and R.sup.6 are the same or different and each is a lower alkyl, R.sup.5 is amino or a lower alkyl, A is an alkylene, X is N or CH and m and n are the same or different and each is 0 or 1, with the proviso that when X is N, R.sup.5 is amino.

  二氢吡啶衍生物及其酸盐是用作心血管疾病的预防或治疗药物，所述二氢吡啶衍生物具有以下结构式：其中R.sup.1是氢原子或芳基，R.sup.2和R.sup.3相同或不同，每个都是芳基，R.sup.4和R.sup.6相同或不同，每个是较低烷基，R.sup.5是氨基或较低烷基，A是烷基，X是N或CH，m和n相同或不同，每个为0或1，但当X为N时，R.sup.5为氨基。
• Dihydropyridine derivatives, their production and use
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP0138505A2

  公开（公告）日：1985-04-24

  Dihydropyridine derivatives and acid addition salts thereof which are of use as prophylactic or/and therapeutic drugs for cardiovascular diseases, said dihydropyridine derivatives having the formula wherein R1 is a hydrogen atom or an aryl, R2 and R3 are the same or different and each is an aryl, R4 and R6 are the same of different and each is a lower alkyl, R5 is amino or a lower alkyl, A is an alkylene, X is N or CH and m and n are the same or different and each is 0 or 1, with the proviso that when X is N, R5 is amino.

  可用作心血管疾病预防或/和治疗药物的二氢吡啶衍生物及其酸加成盐，所述二氢吡啶衍生物具有以下式子 式中 R1 是氢原子或芳基、 R2 和 R3 相同或不同，且各自为芳基、 R4 和 R6 相同或不同，各自为低级烷基、 R5 是氨基或低级烷基、 A 是亚烷基、 X 是 N 或 CH，以及 m 和 n 相同或不同 且各自为 0 或 1、 但当 X 为 N 时，R5 为氨基。
• Substituted imidazolyl-alkyl-piperazine and -diazepine derivatives
  申请人：SYNTEX PHARMACEUTICALS LTD.

  公开号：EP0289227A1

  公开（公告）日：1988-11-02

  Substituted imidazolyl-alkyl-piperazine and diazepine derivatives of Formula A: wherein:     R¹ is aryl;     R² is aryl, C₁₋₄ alkyl, or hydrogen;     R³ is C₁₋₄ alkyl, hydroxy, or hydrogen;     R⁴ is aryl;     R⁵ is aryl;     m is two or three;     n is zero, one or two, provided that when R³ is hydroxy, n is one or two; and     q is zero, one, two, or three; and the pharmaceutically acceptable salts thereof, are useful for treating mammals having a variety of disease states, such as stroke, epilepsy or epileptic psychotic symptoms, hypertension, angina, migraine, arrhythmia, thrombosis, embolism, acute cardiac failure, irritable bowel syndrome, neurodegenerative diseases such as Alzheimer's or Huntington's chorea, diuresis, ischemia such as focal and global ischemia or cerebrovascular ischemia induced by cocaine abuse, and also for treatment of spinal injuries.

  式 A 的取代咪唑烷基哌嗪和二氮杂卓衍生物： 其中 R¹ 是芳基； R² 是芳基、C₁₋₄ 烷基或氢； R³ 是 C₁₋₄ 烷基、羟基或氢； R⁴ 是芳基； R⁵ 是芳基； m 是两个或三个； n 为 0、1 或 2、 当 R³ 为羟基时，n 为一或二；以及 q 为零、一、二或三； 及其药学上可接受的盐类，可用于治疗哺乳动物的多种疾病，如中风、癫痫或癫痫性精神症状、高血压、心绞痛、偏头痛、心律失常、血栓形成、栓塞、急性心力衰竭、肠易激综合征、神经性肠病、心绞痛、偏头痛、心律失常、血栓形成、栓塞、急性心力衰竭、肠易激综合征、神经退行性疾病（如阿尔茨海默氏症或亨廷顿舞蹈症）、利尿、缺血（如局灶性和全身性缺血或滥用可卡因引起的脑血管缺血），以及用于治疗脊柱损伤。
• Bis-S-alkylbenzene derivatives
  申请人：GREEN CROSS CORPORATION

  公开号：EP0319947A2

  公开（公告）日：1989-06-14

  Compounds with the formula : wherein R₁ and R₂ each represents an alkyl group; R₃ represents a hydrogen atom or an alkyl, an acyl, an alkoxyalkyl, an alkylcarbamoyl or a phosphate group: and R₄ represents a group of the following formula: -CmH2m-R₅ wherein R₅ represents a hydrogen atom, an unsubstituted cycloalkyl group, or a cycloalkyl group substituted with a hydroxyl group; and m is an integer of 3 to 15; a group of the following formula: -CnH2n-O-R₆ wherein R₆ represents a hydrogen atom, an acyl group, an unsubstituted alkyl group, or an alkyl group substituted with a hydroxyl group; and n is an integer of 3 to 15; or a benzhydrylpiperazinylalkyl group, can be used as lipogenase inhibitors.

  式中 R₁ 和 R₂ 各自代表一个烷基；R₃ 代表氢原子或烷基、酰基、烷氧基烷基、烷基氨基甲酰基或磷酸基；以及 R₄ 代表下式中的一个基团： -CmH2m-R₅ 其中 R₅ 代表氢原子、未取代的环烷基或被羟基取代的环烷基；且 m 是 3 至 15 的整数；下式中的一个基团： -CnH2n-O-R₆ 其中 R₆ 代表氢原子、酰基、未取代的烷基或被羟基取代的烷基；且 n 为 3 至 15 的整数；或二苯甲基哌嗪基烷基。